Hopp til innholdet
innsidehandel

← Alle transaksjoner

ArcticZymes Technologies - Primary insider trading

ArcticZymes Technologies ASA (AZT) · publisert 7. november 2024 kl. 14:52 · vis på NewsWeb

Transaksjoner

PersonRolleTypeVolumPrisDatoISINHandelsplassTolket via
Sharon Brownlow Board member / primary insiderother Uklassifisert10,570,9378 GBPNO0010014632rules · til gjennomgang
Michael Akoh CEO / primary insiderother Uklassifisert7,6613,26 NOKNO0010014632rules · til gjennomgang

Vedlegg

Meldingstekst

(Tromsø 07 November 2024) Michael Akoh, CEO has on 07 November purchased 7.660 shares in ArcticZymes Technologies ASA for NOK 13.26 per share. Following this transaction holds Mr. Akoh 7.660 shares and 200.000 options in the company. Sharon Brownlow,  Board member has on 7 November purchased 10.570 shares in ArcticZymes Technoloiges ASA for GBP 0.9378 per share. Following this transaction holds Mrs. Brownlow 10.570 shares in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For additional information, please contact Børge Sørvoll CFO +4795290187 ir@arcticzymes.com About ArcticZymes Technologies ASA ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre. ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents. For more information, please visit the website: www.arcticzymes.com
ArcticZymes Technologies - Primary insider trading · Innsidehandel